FindTrial
Sign In

Effects of rosuvastatin and sevelamer in coronary calcification in chronic kidney disease patients

Effects of rosuvastatin and sevelamer in coronary calcification in chronic kidney disease patients not on dialysis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
REBEC
Registry ID
RBR-6pngwz
Enrollment
Unknown
Registered
2011-07-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary calcification

Interventions

Group A - Rosuvastatin 10mg MID,for 12 months Group B - Sevelamer 800mg TID,for 12 months Group C - control (not using a special drug)
drug

Sponsors

UNIVERSIDADE FEDERAL DE SAO PAULO
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients were older than 18 years and were followed by a nephrologist for at least 03 months.

Exclusion criteria

Exclusion criteria: Exclusion criteria were the presence of chronic inflammatory diseases, active malignancy, human immunodeficiency virus (HIV), viral hepatitis and chronic steroids intake.

Design outcomes

Primary

MeasureTime frame
Coronary calcification progression, determined by coronary tomography at study baseline and after follow up period.—

Countries

Brazil

Contacts

Public ContactMARCELO LEMOS

UNIVERSIDADE FEDERAL DE SAO PAULO

lemosmm@gmail.com11- 5572-0530

Outcome results

None listed

Source: REBEC (via WHO ICTRP)